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Members of the transforming growth factor- superfamily
play essential roles in both the pluripotency and differentia-
tion of embryonic stem (ES) cells. Although bone morpho-
genic proteins (BMPs) maintain pluripotency of undifferen-
tiated mouse ES cells, the role of autocrine Nodal signaling is
less clear. Pharmacological, molecular, and genetic methods
were used to further understand the roles and potential inter-
actions of these pathways. Treatment of undifferentiated ES
cells with SB431542, a pharmacological inhibitor of Smad2
signaling, resulted in a rapid reduction of phosphorylated
Smad2 and altered the expression of several putative down-
stream targets. Unexpectedly, inhibition of the Nodal signal-
ing pathway resulted in enhanced BMP signaling, as assessed
by Smad1/5 phosphorylation. SB431542-treated cells also dem-
onstrated significant induction of the Id genes, which are known
direct targets of BMP signaling and important factors in ES cell
pluripotency. Inhibition of BMP signaling decreased the
SB431542-mediated phosphorylation of Smad1/5 and induc-
tion of Id genes, suggesting that BMP signaling is necessary for
some Smad2-mediated activity. Because Smad7, a known inhib-
itory factor to both Nodal and BMP signaling, was down-regu-
lated following inhibition ofNodal-Smad2 signaling, the contri-
bution of Smad7 to the cross-talk between the transforming
growth factor- pathways in ES cells was examined. Biochemi-
cal manipulation of Smad7 expression, through shRNA knock-
down or inducible gene expression, significantly reduced the
SB431542-mediated phosphorylation of Smad1/5 and induc-
tion of the Id genes.We conclude that autocrineNodal signaling
in undifferentiated mouse ES cells modulates the vital pluripo-
tency pathway of BMP signaling.
Mouse embryonic stem (ES)2 cells are derived from the inner
cell mass of the early blastocyst. It is from the inner cell mass
that the germ layers arise to produce all cell types of the adult.
The capacity of ES cells to either self-renew or differentiate into
cells of the three germ layers provides an excellent tool for
studying early embryonic development, including self-renewal
and pluripotency (1). Some of the essential factors controlling
ES cell pluripotency have been identified; however, additional
work is necessary to identify other functional signaling path-
ways that impinge upon the ES cell phenotype, to determine
genes that are regulated by these pathways, and to discover how
the various pathways interact. Applications of this work will
yield insights into the promising use of stem cells for regenera-
tive therapies.
ES cells can be maintained as pluripotent cells when grown
onmitotically inactivated embryonic fibroblasts orwhen grown
in media supplemented with leukemia inhibitory factor (LIF
(2, 3)). Additionally, under serum-free culture conditions, sig-
naling through the bone morphogenetic protein (BMP) path-
way is essential for maintaining mouse ES cell pluripotency (4,
5). The combination of LIF and BMP4 inhibits multiple differ-
entiation-inductive signals, a capability that can be replicated
without extrinsic stimuli through pharmacological inhibition
of fibroblast growth factor 4 and glycogen synthase kinase 3
signaling (6). BMP signaling mediates ES cell pluripotency
through induction of the Id genes (Inhibitors of differentiation
(5)), which are negative regulators of basic helix-loop-helix
transcription factors and play important roles in during early
development and in embryonic and somatic stem cells (7, 8).
Expression of Id1, a direct target of BMP4, liberates ES cells
from BMP or serum dependence (5, 9). The central require-
ment for active BMP signaling in maintaining ES cells under
serum-free conditions is clear, yet its regulation and interac-
tions with other pathways are important questions in ES cell
biology.
BMPs are members of the transforming growth factor
(TGF)- superfamily, whose diversemembers play vital roles in
embryonic development and in ES cell biology (10, 11). The
ligands, including TGF-, Activin, Nodal, and the BMPs, bind
to the extracellular domain of the type II receptors. Binding
induces activation of type I receptors, including the Activin
receptor-like kinases (ALKs) 1–7 (12). Activin andNodal signal
via ALK4, ALK5, and ALK7, whereas the BMPs convey signal-
ing through ALK2, ALK3, and ALK6. In the canonical signaling
pathwaymodel, intracellular transduction ismediated by phos-
phorylation of receptor-regulated Smad proteins via activated
type I receptors. Smad2 and Smad3 are activated by Activin
and Nodal signaling, whereas Smad1, Smad5, and Smad8 are
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substrates for BMP-activated receptors (13). Phosphorylated
Smads (pSmad) formheteromeric complexes with co-mediator
Smad4, enter the nucleus, and interact with co-activators and
transcription factors to affect gene transcription. Moreover,
inhibitory Smads (Smad6 and Smad7) inhibit activation of
receptor-regulated Smad proteins and function as feedback
modulators of pathway activity (14).
ES cells have an active Nodal-Smad2 signaling axis (15).
Nodal is highly expressed in ES cells, suggesting significant
autocrine activity of this pathway. Stimulation of ES cells with
recombinant Activin or Nodal enhances Smad2 phosphoryla-
tion and increases ES cell proliferation (16). Alternatively, phar-
macological inhibition of pSmad2 signaling and inhibition by
Smad7 overexpression decrease ES cell proliferation (16).
Transcriptional targets of Smad2 in ES cells includemany feed-
back regulatory factors such as Smad7, Lefty, and Bambi (17).
However, the actions of downstream target genes of Nodal-
Smad2 signaling and interactions with other critical signaling
pathways are not known.
In this work, we sought to define the activity of Nodal signal-
ing and its interaction with the BMP pathway in undifferenti-
ated mouse ES cells. Using pharmacological, molecular, and
genetic methods, these efforts demonstrated that inhibition of
Nodal signaling indirectly enhanced the activation of the BMP
substrates Smad1/5 and increased the expression of down-
stream BMP target genes. Nodal signaling regulated Smad7
expression, which feeds back to inhibit both the Nodal and
BMP pathways in ES cells. This work uncovered an interdepen-
dence of the Nodal-Smad2 and BMP-Smad1/5 signaling path-
ways in undifferentiated ES cells and defines potential mecha-
nisms for these pathways in ES cell maintenance.
EXPERIMENTAL PROCEDURES
ES Cell Culture—E14Tg2A (E14) ES cells were maintained
on feeder-free, gelatin-coated plates in ES media as described
before (18, 19). Experiments were conducted in serum-free,
defined media (5, 20), supplemented with 103 units/ml LIF and
10 ng/ml BMP4 (R&D). ES cells were treated with 10 ng/ml
BMP4, 10 ng/ml Activin (R&D), 5 M SB431542 (Sigma), 0.5
MA-83-01, and 5Mdorsomorphin (Sigma) at the noted con-
centration and for 24 h unless specifically noted otherwise.
DMSO was applied at the same volume as SB431542, A-83-01,
or dorsomorphin as a vehicle control. Analyses of time-course
treatments of SB431542 and BMP4were performed by applica-
tion of each treatment to sustained cultures; thus, over the
length of the time course the media stayed constant and only
the treatments were added at each time point.
Standard protocols (19) were used to generate homozy-
gous Smad2m1Mag ES cells from blastocysts. In brief, timed
matings were performed by crossing Smad2m1Mag heterozy-
gous females with Smad2m1Mag heterozygous males (21) car-
rying the Rosa26-lacZ allele (22). Blastocysts were flushed
from these matings, and inner cell mass outgrowths were
cultured in ES media on gelatin-coated dishes to establish
cell lines. DNA was isolated for genotyping of the Smad2m1Mag
allele, and X-Gal staining (23) was performed to identify cell lines
carrying the Rosa26-lacz allele. Two lines of each genotype were
used for the analysis.
RNAAnalysis—RNAwas isolated usingQiagen columns and
initially analyzed with the Mouse Genome 430A Array from
Affymetrix. Microarray data were deposited to the Gene
Expression Omnibus (GSE17879). For gene expression analy-
sis, cDNAwas synthesized (Applied Biosystems), and quantita-
tive real-time PCR analysis was performed using TaqMan
primer sets with the 7500 Real Time PCR system (Applied Bio-
systems). Specific ABI TaqMan Primer/Probe assay identifica-
tion numbers are available upon request.
Protein Analysis—Cells were lysed using radioimmune pre-
cipitation assay buffer with Halt Protease and Phosphatase
Inhibitor Cocktails (Pierce) forWestern analysis. Primary anti-
bodies for pSmad2 (Millipore), Smad2 (Zymed Laboratories
Inc.), pSmad1/5/8 (Cell Signaling), Smad1 (Zymed Laborato-
ries Inc.), glyceraldehyde-3-phosphate dehydrogenase (Santa
Cruz Biotechnology), Smad7 (R&D), and FLAG (Sigma) were
incubated overnight at 4 °C and followed with incubation of
appropriate secondary antibodies.
Luciferase Assays—E14 ES cells were plated 1 day prior to
transfection on gelatin-coated 24-well plates and transfected
with pGL2-Id1 Luciferase (1585 to 88 of promoter; Add-
gene plasmid 16048 (24)), and pGL4.74 [hRluc/TK] (Promega)
using Lipofectamine 2000 (Invitrogen). Following transfection,
ES media was change to defined media with LIF and BMP4 for
24 h. Cells were then grown in defined media with LIF and
treated with BMP4, SB431542, or BMP4 plus SB431542 for an
additional 24 h. Firefly luciferase activity in cell lysates was
measured and normalized to expression of TK-Renilla
luciferase.
The Activin-responsive reporter pGL3-CAGA12-luciferase
(25) was co-transfected with pGL4.74 [hRluc/TK] into control
and Smad2m1Mag homozygous ES cells. The cells were grown in
defined media with LIF and 20 ng/ml BMP4 and treated with
Activin or SB431542 for the final 24 h. Lysateswere analyzed for
luciferase readings.
RNA Knockdown—Two methods were utilized for knock-
down of specific target genes. For knockdown of Nodal and
TGF-1, specific siRNAs (Dharmacon) were transfected via
lipofection following the manufacturer’s instructions. Changes
in gene expression were compared with a non-targeting siRNA
after 48 h. For knockdown of Smad7, plasmids expressing
shRNAs (Open Biosystems) were transfected into ES cells via
lipofection and screened for efficient knockdown. The hairpin
targeting 5-CTCCAGATACCCAATGGATTT-3 (bp 920–
940, TRCN0000096053) produced the strongest Smad7 knock-
down and was used in subsequent experiments. A non-target-
ing hairpin (26) was cloned into pLKO.1. The non-targeting
and Smad7 shRNAs were transfected into ES cells. One day
after transfection, the cells were passaged and plated in defined
media with LIF, BMP4, and puromycin to select for cells with
transient expression of pLKO.1 constructs. After selection, the
ES cellswere treatedwith appropriatemedia conditions for 24 h
after which the cells were harvested for RNA or protein
analyses.
Inducible Smad7 Overexpression—CRE-mediated recombi-
nation was used to generate an ES cell line with doxycycline-
inducible Smad7, as described previously (27). In brief, a cDNA
encoding FLAG-Smad7 was cloned into the engineered PALP
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targeting vector, and the resulting construct was co-electropo-
rated with a Cre-expressing plasmid (pOG231, Addgene Plas-
mid 17736 (28)) in Ainv15 cells. The Ainv15 cell line, derived
from E14mES cells, contains a reverse tetracycline transactiva-
tor for the tet-ON system in theRosa26 locus and a tet response
element, a loxP site, and a neomycin resistance gene lacking an
initiation codon in the Hprt locus (27, 29). After selection in
media supplemented with G418, clones with appropriate
recombination were confirmed via PCR genotyping, tested for
doxycycline-inducible expression, and karyotyped. For RNA
and protein analyses, cells were treated with doxycycline for 6 h
prior to treatment with SB431542 and then co-treated with
doxycycline and SB431542 for 24 h.
Data Analysis—Results were graphed to represent means 
S.E. of the mean. RNA analyses were performed in at least trip-
licate samples. Student t-tests were performed to determine
statistical significance of the data with a p value of 0.05 con-
sidered statistically significant.
RESULTS
Smad2 Signaling Regulates Transcription of Multiple Feed-
back andPluripotencyGenes—Todetermine the target genes of
Smad2 signaling in undifferentiated ES cells, changes in gene
expression were examined following treatment with recombi-
nant Activin or SB431542 under defined media culture condi-
tions (20). SB431542 specifically inhibits ALK4/5/7 receptor
signaling as a competitive inhibitor of ATP binding to the
kinase domain and has no effect on BMP-regulated ALKs or
other kinase pathways (30, 31). In mouse ES cells, recombinant
Activin has been shown to produce stronger Smad2 phosphor-
ylation at lower concentrations than commercially available
recombinantNodal (16); thus, Activinwas used to stimulate the
Smad2 pathway in this analysis. In non-manipulated ES cells
grown in serum-free media, substantial pSmad2 was observed
viaWestern analysis (Fig. 1A), demonstrating an autocrine sig-
naling activity for this pathway. Activin stimulation increased
pSmad2 in ES cells after 2 h, while treatment with SB431542 for
24 h virtually eliminated pSmad2. Total Smad2 expression
remained unchanged through these manipulations.
Changes in gene expression in ES cells treatedwithActivin or
SB431542 was first analyzed through Affymetrix microarrays
and then confirmed using real-time quantitative PCR (rtPCR,
Fig. 1B). The inhibition of Smad2 signaling resulted in more
numerous and larger magnitude changes in gene expression
than Smad2 pathway stimulation. This observation is consis-
tent with the idea that Smad2 signaling is active via autocrine
mechanisms inmouse ES cells. No changes in the expression of
the core pluripotency factors such as Nanog and Pou5f1 (Oct4)
were observed in the short timeframe examined in these
expression analyses (data not shown). Inhibition of Smad2 sig-
naling acted both to repress and derepress gene expression.
Altered in Smad2 activity produced the greatest gene expres-
sion changes in the Lefty genes, secretedNodal antagonists that
are highly expressed in ES cells and play vital roles in left/right
asymmetry in the developing embryo (32). Loss of pSmad2
reduced the expression of the Lefty genes to an amount greatly
reduced from basal expression, whereas stimulation of pSmad2
increased Lefty1 and Lefty2 expression 3-fold, the greatest
observed increase in gene expression associated with Activin
treatment. Inhibition of Smad2 signaling via SB431542 signifi-
cantly diminished the expression of multiple other develop-
mentally regulated genes, including Brachyury (T), Follistatin
(Fst), Fgf8, Spsb1, Pitx2, andMixl1, and significantly attenuated
the expression of components of the TGF- family signaling
pathway, including Nodal and Smad7.
Interestingly, inhibition of Smad2 signaling enhanced the
expression of the Id genes, transcriptionalmodulators that have
FIGURE 1. ES cell gene expression analysis following Smad2 stimulation,
inhibition, and genetic mutation. ES cells were treated with Activin for 2 h or
with SB431542 (SB, pSmad2 inhibitor) for 24 h in defined media with LIF and 20
ng/ml BMP4. A, immunoblot analysis of Smad2 phosphorylation following
Activin stimulation or SB treatment. B, gene expression of Activin- and SB-treated
ES cells was compared with untreated ES cells using rtPCR. The dotted line repre-
sents a 2-fold change in gene expression. C, rtPCR analysis of Lefty1 expression
following siRNA knockdown of Nodal and TGF-1. D, Smad2m1Mag mutant ES cells
activated the Smad-binding element (CAGA12) luciferase reporter significantly
less than control cells. E, rtPCR analysis revealed that Smad2m1Mag mutant ES cells
had significantly decreased Smad7 and Lefty1 expression and increased Id1
expression. *, p  0.05. Abbreviations: T, Brachyury; Fst, Follistatin.
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been shown to be vital in BMP-mediated ES cell pluripotency
(5). Smad2 inhibition induced Id1, Id2, and Id3 expression over
2-fold, whereas Activin treatment had the opposite effect and
reduced Id gene expression by almost half (Fig. 1B). Treat-
ment with SB431542 also derepressed the expression of Ascl2
(Mash2) and Gata2, genes that are not expressed in undiffer-
entiated ES cells. Although the developmental expression of
Ascl2 andGata2 is complex, both genes are highly expressed in
the developing trophectoderm. These results define a cohort of
developmentally important genes that are regulated by Smad2
signaling in undifferentiated mouse ES cells.
The microarray and biochemical results suggest an active
autocrine signaling pathway mediated by Smad2 in ES cells.
The microarray data were examined to determine which of the
TGF-1-related ligands are expressed in ES cells and could
mediate this signaling. The Nodal ligand had by far the strong-
est mRNA expression in ES cells of all ALK4/5/7 ligands, sug-
gesting the autocrine Smad2 activation is mediated by expres-
sion and secretion of Nodal. However, the TGF-1 ligand
demonstrated low expression in ES cells. To confirm thatNodal
is the major mediator of pSmad2 activity in ES cells, Nodal and
TGF-1 expression were reduced through siRNA transfection,
and known Smad2 gene targets were analyzed. siRNA knock-
down of Nodal significantly down-regulated Lefty1, a highly
responsive target of Smad2 signaling, whereas TGF-1 knock-
down had no effect of Lefty1 expression (Fig. 1C). Thus, treat-
ment of ES cells with SB431542 primarily inhibits autocrine
Nodal signaling.
To confirm the activity of the Nodal-Smad2 axis via non-
pharmacological methods, we generated ES cells that carry a
homozygous Smad2 mutation, Smad2m1Mag (21). Previous in
vivo analysis has shown that the Smad2m1Mag mutation is a
severe reduction of the functional allele. The reduced function
of this Smad2 mutation was confirmed with the homozygous
mutant ES cells by chimeric analysis and via protein interaction
analysis (supplemental Fig. 1). The transcriptional activity of
the Smad2m1Mag allele was assayed via transient transfection of
the CAGA12 luciferase reporter, which is responsive to TGF-
and Activin but not BMP stimulation (25, 33). Smad2m1Mag ES
cells activated the CAGA12 reporter significantly less than con-
trol cells and failed to enhance reporter activity in response to
Activin stimulation (p  0.05, Fig. 1D). The basal CAGA12
reporter activity in Smad2m1Mag ES cells may be from the low
level of Smad3 present in ES cells (33, 34).
To determine if Smad2m1Mag mutant ES cells also exhibited
similar gene expression defects as SB431542-treated ES cells,
expression of Smad7, Lefty1, and the Id genes were analyzed in
the mutant ES cells. Smad2 mutant ES cells expressed signifi-
cantly lower Smad7 and Lefty1 mRNA than control heterozy-
gous cells (p  0.05, Fig. 1E). Correspondingly, Id1 expres-
sion was significantly up-regulated over 1.5-fold (p  0.05).
Although Id2 and Id3 also had increased expression, the
changes did not reach statistical significance. Thus, gene
expression changes after pharmacological inhibition of Nodal
signaling are consistent with genetic perturbation of Smad2
signaling. Overall, these data support an autocrine signaling
pathway in undifferentiated ES cells mediated by Nodal and
Smad2 that regulates the expression of a substantial number of
genes.
Nodal Inhibition Eliminates pSmad2 with Delayed Induction
of pSmad1/5 and Id Gene Expression—Several of the genes
identified as being regulated by Smad2 signaling in ES cells
include regulators of the Nodal-Smad2 signaling axis itself.
Although changes in expression of Lefty1, Lefty2, and Nodal
will feedback to affect signaling through the Nodal pathway,
modulation of Follistatin and Smad7 have the ability to affect
multiple pathways, including BMP-mediated activity (35, 36).
Given the importance of the BMP signaling pathway in main-
taining ES cell pluripotency (5), wewanted to determine ifmod-
ulation of Nodal signaling affected the BMP signaling axis in
undifferentiated ES cells.
The level of intracellular BMP signaling activity was moni-
tored by examining the phosphorylation of Smad1/5 following
inhibition of Nodal signaling in a detailed time course. Treat-
ment with SB431542 significantly decreased pSmad2 levels
after 0.5 h (Fig. 2A). Surprisingly, Smad1/5 phosphorylation
FIGURE 2. Inhibition of Nodal-Smad2 signaling induced delayed Smad1/5
phosphorylation and Id induction. A, time course of SB431542 (SB) treat-
ment to determine the effects of Nodal-Smad2 inhibition on Smad protein
levels and phosphorylation states. B, rtPCR analysis of Id genes and Smad7
during SB time course. Samples are compared with control cells grown in
defined media with LIF and BMP4. C, rtPCR analysis of Id genes in response to
BMP4, SB, and BMP plus SB. Gene expression compared with cells grown in
defined media with LIF. D, dual luciferase reporter assay for Id1 promoter
reporter. ES cells were transfected, grown in designated media for 24 h, and
assayed for luciferase activity. *, p  0.05 compared with control; #, p  0.05
compared with single treatment of BMP4 or SB.
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increased after 3 h of SB431542 treatment. Previous work has
indicated that SB431542 is a specific inhibitor of ALK4/5/7
kinase activity and has no affect on the type I BMP receptors
that modulate Smad1/5 phosphorylation (30); thus, this effect
is not due to direct pharmacological modulation of the BMP
receptor kinase activity. The temporal lag of increase in
Smad1/5 phosphorylation compared with the decrease in
Smad2 phosphorylation suggests that the enhanced phosphor-
ylation of Smad1/5 in response to Nodal inhibition is likely
indirect.
To verify the change in phosphorylation of BMP-regulated
Smads in response to inhibition of Nodal signaling, a second
small molecule inhibitor of ALK4/5/7, A-83-01, was used.
A-83-01 is a more potent inhibitor of the ALK4/5/7 receptors
that prevents phosphorylation of Smad2 but has no effect on
type I BMP receptors (37). Treatment with either 5 M
SB431542 or 0.5 M A-83-01 induced similar increases in
pSmad1/5 levels after 24 h (supplemental Fig. 2A). The
enhancement of pSmad1/5 in response to SB431542 was also
observed in cells grown in definedmedia lacking BMP4 supple-
mentation in the media. Also, stimulation with recombinant
Activin, with or without BMP4 supplement, lowered the phos-
phorylation state of Smad1/5. Thus, multiple modes of Smad2
signal perturbation reveal changes in BMP signaling.
Inhibitory Smad7 is able to antagonize both Nodal and BMP
signaling and participate in the cross-talk between the path-
ways (36). Because Smad7mRNA expression was reduced, but
not eliminated, in response to SB431542 treatment (Fig. 1B),
the mRNA and protein expression of Smad7 were analyzed in
detail during the time course of SB431542 treatments. Smad7
transcript levels dropped almost 20% after 1 h and declined by
more than half within 2 h of SB431542 treatment (Fig. 2B).
Smad7 protein levels declined after 2 h of SB431542 treatment
and were significantly down-regulated between 3 and 4 h of
treatment (Fig. 2A). This result indicates that Smad7 is an
immediate early response gene of Nodal signaling. The decline
of Smad7 levels in response to SB431542 coincided with the
increased phosphorylation of Smad1/5. Correspondingly, the
expression of theBMP targets Id1, Id2, and Id3was significantly
enhanced after 3 h of Nodal inhibition and increased 2- to
3-fold by 24 h (Fig. 2B, p  0.05). The SB431542-mediated
Smad7 repression and Id induction was retained during long
term culture (supplemental Fig. 2B, p 0.05). This time-course
analysis of the events following inhibition of Smad2 signaling
in undifferentiated ES cells suggests that the activation of
pSmad1/5 and subsequent induction of BMP-target genes may
be controlled indirectly by Nodal-Smad2 signaling.
Active BMP4-Smad1/5 Pathway Is Necessary for Id Induction
by Nodal Inhibition—Previous work has indicated that the Id
genes are direct targets of BMP signaling inmouse ES cells (5, 9,
38). This was confirmed via a time-course analysis of BMP4
stimulation. ES cells were grown in serum-free conditions lack-
ing BMP4 only for 24 h prior to the time course to retain proper
conditions for ES self-renewal. Application of recombinant
BMP4 stimulated phosphorylation of Smad1/5 within 45 min
(Fig. 3A). Interestingly, the maximum level of Smad1/5 phos-
phorylation occurred after 1 h of BMP4 stimulation, was re-
duced at 2 h, and eventually reached steady-state levels by 4 h.
The initial spike in BMP-Smad1/5 signaling is likely moderated
bymultiple feedbackmechanisms (36, 39). No significant effect
on pSmad2 was observed during the time course of BMP treat-
ment, indicating that BMPactivation did not significantlymod-
ulate Smad2 signaling.
The timing of Id induction in response to BMP treatment
closely followed the phosphorylation and activation of Smad1/5
(Fig. 3B). Expression of Id1, Id2, and Id3 was significantly ele-
vated after 45 min of BMP4 exposure (p  0.05), a time point
that strongly correlates with the phosphorylation of Smad1/5.
Id1 expression displayed a peak induction of 11-fold by 2 h after
BMP treatment, and a steady-state level of almost 7-fold.
Smad7 expressionwas not significantly affected by BMP4 stim-
ulation (data not shown). Thus, because the Id genes are very
early targets of BMP-Smad1/5 signaling, the correlation of the
SB431542-mediated Id induction between 3 and 6 h and the
phosphorylation of Smad1/5 at 3 h suggests the Id genesmay be
indirect targets of Nodal inhibition via BMP signaling.
Wenext determined if co-stimulationwith exogenous BMP4
is required for the SB431542-mediated Id gene up-regulation.
ES cells were cultured in defined media with LIF and supple-
mented with BMP4, SB431542, or BMP4 plus SB431542 for
24 h. Treatment with either BMP4 or SB431542 resulted in
similar increases in Id expression (Fig. 2C). Concurrent treat-
ment with BMP4 plus SB431542 induced significantly higher Id
induction than either treatment alone, suggesting that the tran-
scriptional responses are additive and correlating with higher
overall pSmad1/5 levels (supplemental Fig. 2A). Moreover,
stimulation with BMP4 and SB431542, alone or in combina-
tion, activated an Id1 luciferase reporter (24) that is regulated
by the 1.5-kb upstream Id1 promoter sequence (Fig. 2D). Thus,
FIGURE 3. BMP4 time course in ES cells. ES cells were grown in defined
media with LIF and BMP4. During the last 24 h, BMP4 was removed from the
media and then supplemented at the indicated time points. A, effects of
BMP4 stimulation on pSmad1/5 and pSmad2 were assayed through immu-
noblots with Smad1 and Smad2 expression noting equal loading. B, rtPCR
analysis of Id genes and Smad7 during the BMP4 time course. Samples are
compared with control cells grown in defined media with LIF. *, p  0.05.
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both Smad2 signaling inhibition and BMP4 stimulation
enhance Id expression to similar levels in the short term ES cell
culture treatments, and this effect is additive with concurrent
treatments.
Dorsomorphin, a selective small-molecule inhibitor to the
type I BMP-responsive receptors (ALK2/3/6), has recently been
identified to block BMP-mediated Smad1/5 phosphorylation
(40, 41). To determine if the Id induction elicited by SB431542
treatment is indirectly mediated through BMP signaling, an
analysis of cells treated with SB431542 and dorsomorphin was
performed. ES cells were cultured for 24 h in BMP4, SB431542,
or BMP4 plus SB431542 with and without dorsomorphin. Dor-
somorphin treatment resulted in a substantial reduction of
pSmad1/5 in response to treatment with either BMP4 or
SB431542 (Fig. 4A). Although dorsomorphin also lowered
pSmad1/5 levels mediated by simultaneous BMP4 and
SB431542 treatments, the amount of activated pSmad1/5 was
substantially higher than in singly treated cells. The remaining
amount of pSmad1/5 was likely caused by a high number of
active ALK2/3/6 receptors stimulated by the dual treatment of
BMP4 and SB431542. Thus, inhibition of Nodal signaling pri-
marily induces phosphorylation of Smad1/5 indirectly through
BMP-responsive receptors. Furthermore, dorsomorphin treat-
ment of ES cells significantly reduced expression of Id1 and Id2
in response to BMP4, SB431542, or both BMP4 and SB431542
(Fig. 4B, p  0.05). Id3 expression failed to significantly change
in response to ALK2/3/6 inhibition. The protein and transcript
analyses indicate that SB431542-mediated Smad1/5 phosphor-
ylation and Id induction require active BMP signaling.
Manipulation of Smad7 Levels Alters SB431542-mediated
Phosphorylation of Smad1/5 and Induction of the Id Genes—
The signaling pathways of the two TGF- subfamilies interact
at many levels, including ligand activation, receptor complex
formation, and Smad activation (36). To determine the mech-
anism of interaction between Nodal inhibition and BMP-
Smad1/5 activation in ES cells, we analyzed multiple factors
that may connect the pathways. First, as the receptor-regulated
Smads from the Nodal and BMP pathways both bind to co-
Smad4 (39), the Smad4 released by Smad2 inhibition may
increase the availability of Smad4 to form heteromeric com-
plexes with pSmad1/5 and therefore activate the BMPpathway.
However, when Smad4 is overexpressed in ES cells via transfec-
tion of an expression plasmid (42), no effect onBMP signaling is
observed, as assessed by phosphorylation of Smad1/5 and Id1
gene expression (supplemental Fig. 3). Also, SB431542 treat-
ment still retained the ability to increase pSmad1/5 and Id1
expression (supplemental Fig. 3). This result indicates that
Smad4 levels are not limiting in ES cells.
Second, Follistatin was shown to be down-regulated follow-
ing Nodal inhibition in ES cells (Fig. 1B). Follistatin is a well
characterized antagonist of Activin signaling that can antago-
nize BMP signaling in some systems (43, 44) but not others (45).
To determine if the low level of Follistatin expression in ES cells
modulates BMP signaling in mouse ES cells, follistatin levels
were reduced via siRNA transfection, and Id1 expression was
examined to measure BMP-Smad1/5 activity. siRNAs against
follistatin reduced Follistatin expression 50%, similar to
treatment with SB431542 (supplemental Fig. 4). Decreased Fol-
listatin expression did not affect basal Id1 expression or the
SB431542-mediated induction of Id1, suggesting that regula-
tion of follistatin does not contribute to the connectivity
between Nodal-Smad2 and BMP-Smad1/5 signaling.
As Smad7 expression was also reduced in response to inhi-
bition of Nodal signaling (Fig. 2A,B), its down-regulation may
be responsible for the SB431542-mediated enhancement of the
BMP signaling pathway. Smad7 can antagonize both major
TGF- superfamily signaling axes (46, 47) and has been shown
to be an important component of the cross-talk between Nodal
and BMP signaling (36). Modulation of Smad7 levels was per-
formed to determine the role of Smad7 in interpathway com-
munication in ES cells. To lower Smad7mRNA levels, ES cells
were transiently transfected with plasmids expressing shRNAs
against either a non-targeting sequence or Smad7. Cells
expressing the shRNA targeting Smad7 produced a reduction
of Smad7 mRNA and protein to 40% that of control cells
(Fig. 5A). This level of knockdown is similar to the decrease of
Smad7mRNA in response to SB431542 treatment. To overex-
press Smad7, a doxycycline-inducible system was employed
(27, 29). Via CRE-mediated recombination, a FLAG-Smad7
cDNA was inserted into a doxycycline-regulated locus in
Ainv15 ES cells (Fig. 5E). Upon treatment with doxycycline,
Smad7 is overexpressed 2- to 3-fold (Fig. 5G).
The phosphorylation state of receptor-regulated Smad pro-
teins and the expression of downstream genes were analyzed
after modulation of Smad7 levels. ES cells demonstrated signif-
icantly enhanced Smad1/5 phosphorylation and Id induction
following 48-h knockdown of Smad7 (Fig. 5, B andD, p 0.05).
Knockdown of Smad7 also increased the level of pSmad2 in
Activin-treated cells and expression of Pitx2, a target of Smad2
signaling identified in the microarray studies (Fig. 5, B and C).
FIGURE 4. Inhibition of BMP4 signaling reduced SB431542-mediated
Smad1/5 phosphorylation and Id induction. ES cells were grown in defined
media with LIF and supplemented with combinations of BMP4, SB431542
(SB), and dorsomorphin (Dorso). A, protein lysate was analyzed through
immunoblotting to determine the effect of Dorso, an ALK2/3/6 inhibitor, on
pSmad1/5 levels induced by BMP4, SB, or BMP plus SB. B, gene expression
analysis of Dorso-treated cells by rtPCR demonstrated inhibition of Id1 and
Id2 expression induced through BMP4 and SB stimuli. *, p  0.05.
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Overexpression of Smad7 greatly diminished phosphorylation
of Smad2 and Smad1/5 and dramatically reduced expression of
Id1 (Fig. 5, F and G). Thus, Smad7 actively represses and regu-
lates the endogenous signaling activity of both the Nodal-
Smad2 and BMP-Smad1/5 pathways in undifferentiated ES
cells.
To analyze the role of Smad7 inmediating TGF- interpath-
way communication in ES cells, Smad7 expressionwas knocked
down or overexpressed in SB431542-treated cells. SB431542
treatment of ES cells containing the Smad7 shRNA had lower
Smad7 expression than the Smad7 knockdown alone (supple-
mental Fig. 5). Correspondingly, the SB431542-treated Smad7
shRNAcells also demonstrated enhanced Smad1/5 phosphory-
lation (Fig. 5B), likely due to the additional reduction of inhibi-
tory Smad7. ES cells overexpressing Smad7 demonstrated no
enhancement of pSmad1/5 to Nodal-Smad2 inhibition (Fig.
5F). Furthermore, while SB431542 induced significantly higher
expression of the Id genes in cells transfected with the non-
targeting shRNA, ES cells containing the Smad7 shRNA failed
to significantly induce Id1, Id2, or Id3 expression in response to
SB431542 treatment (Fig. 5D, p  0.05). Moreover, ES cells
overexpressing Smad7 failed to
induce Id1 following SB431542
application (Fig. 5G). These results
clearly demonstrate that reduction
of Smad7 expression is the basis for
enhanced BMP activity in response
to inhibition of Nodal signaling.
These results define a link between
Nodal and BMP signaling pathways




genetic methods were used to dem-
onstrate a previously uncharacter-
ized function for Nodal-Smad2 sig-
naling in modulating the activity of
BMP-Smad1/5 signaling in undif-
ferentiated mouse ES cells. Given
that the BMP signaling axis is an
essential pathway in maintaining
mouse ES cell pluripotency, these
data suggest that Nodal signaling
has the capacity to modulate BMP-
mediated ES cell pluripotency. Via
decreased Smad7 expression, Nodal
inhibition induces expression of the
Id genes through modulation of
BMP signaling. Thus, the Nodal
pathway modulates a signaling
pathway important for ES cell pluri-
potency through regulation of the Id
factors (Fig. 6), which help to main-
tain ES cell pluripotency and inhibit
the differentiation of multiple cell
types (4, 5, 7).
Smad7 Is theCritical Component ofNodal Regulation of BMP
Activity in ES Cells—Although Nodal signaling regulates the
expression of numerous genes, our work shows that the down-
regulation of Smad7 is the major contributor to the intercon-
nectivity of the Nodal and BMP signaling pathways. Smad7,
which is a direct transcriptional target of Smad2 signaling (17),
had enhanced expression following pSmad2 stimulation and
decreased expression after Nodal inhibition. Increased expres-
sion of Smad7 slowed the proliferation of ES cells (Ref. 16 and
data not shown) and inhibited the phosphorylation of Smad2 and
Smad1/5. The inhibitory activity of Smad7 impinges upon both
signaling pathways, and Smad7 has been a well characterized fac-
tor in the cross-talk between the TGF- subfamilies (36). Inhibi-
tion via Smad7 works through multiple potential mechanisms: 1)
compete with Smads for binding to activated type I receptor, 2)
engage E3-ubiquitin ligases to degrade activated type 1 receptors,
and 3) recruit phosphatases to activated type 1 receptor causing
dephosphorylation and deactivation (48). Our work does not dis-
tinguish fromthesepotentialmodelsofSmad7 function inEScells;
thus, further work is necessary to define the mechanism of BMP
signaling modulation by Smad7 in ES cells.
FIGURE 5. Biochemical manipulation of Smad7 expression inhibits SB431524-induced Smad1/5 phos-
phorylation and Id expression. Small-hairpin RNAs (shRNA) were utilized to decrease endogenous Smad7
and determine the responses of the TGF- pathways. ES cells were transfected with pLKO.1-non-targeting
shRNA or pLKO.1-Smad7 shRNA, subcultured, and selected with puromycin for 48 h. During the last 24 h, cells
were treated with various media conditions. A, the characterized Smad7 shRNA produced about a 60% knock-
down of RNA and protein. B, immunoblot analysis of Smad1/5 and Smad2 phosphorylation. C, rtPCR analysis of
Pitx2. D, comparison of Id gene expression in cells treated with BMP4 (control) or BMP4 plus SB431542 (SB).
FLAG-Smad7 was overexpressed through a doxycycline (dox)-inducible system for expression of transgenes in
ES cells (27, 29). E, using CRE-mediated recombination, the FLAG-Smad7 cDNA was inserted into an engineered
locus in Ainv15 ES cells. F, immunoblot of Smad7 and phosphorylation levels of Smad1/5 and Smad2. G, rtPCR
analysis of Id1 following SB treatment of cells overexpressing Smad7. *, p  0.05.
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Little work has been done to understand the complex tran-
scriptional regulation of Smad7 in mouse ES cells. Our results
clearly show a role for Nodal signaling in the transcriptional
regulation of Smad7 in ES cells. Smad7 levels are reduced 0.5-
fold upon inhibition of Nodal signaling by SB431542. In con-
trast, alterations of BMP signaling have very little effect on
Smad7 transcript levels, suggesting BMP signaling is not a
major regulator of Smad7 in ES cells. Although ourwork clearly
shows that Nodal signaling can attenuate BMP signaling, our
work does not address the converse question of whether regu-
lation of Nodal signaling is regulated by the BMP pathway.
Because Smad7 is not substantially regulated by BMP signaling,
any potential regulation ofNodal signaling by theBMPpathway
would likely be via a Smad7-independent mode. Interestingly,
upon inhibition of Nodal signaling by SB431542, ES cells still
retain a significant amount of Smad7 expression (Fig. 2A), indi-
cating an additional Nodal-independent regulatory pathway
that also controls some Smad7 expression. Genome-wide local-
ization studies have shown that both Oct4 and Nanog occupy
distal upstream sites upstream of the Smad7 transcriptional
start site (49), the functions of which have not yet been deter-
mined. Because Smad7 regulates both the BMP and Nodal sig-
naling pathways, a better understanding of Smad7 regulation
will provide valuable information about the control of these
pathways.
Nodal Functions in Pluripotency and Prodifferentiation
Pathways—The microarray analysis of mouse ES cells with
altered Nodal signaling identified a cohort of Smad2-regulated
genes, which confirms and expands on previously published
studies examining pSmad2 positively regulated genes via
expression of an activated type I receptor (17). Although it
remains to be shown, many of these genes are likely directly
regulated by Nodal through transcriptional activation via
Smad2. Many of the genes such as Brachyury, Pitx2, andMixl1
also have significant developmental roles, with a bias toward
genes with roles in gastrulation and mesoderm differentiation.
However, the expression ofmany of these genes is complex and
not restricted to the mesoderm lineage and include expression
in the inner cell mass of blastocyst stage embryos (50–52).
Thus, the expression of many of the developmentally regulated
genes in ES cells likely does not represent overtly differentiated
cell types.
Notably, Nodal inhibition also caused a striking derepression
of genes not expressed in ES cells, including those characteristic
of the trophectoderm lineage such as Ascl2 and Gata2. Nodal
signaling has complex roles in regulating trophoblast differen-
tiation (53). Our findings suggest that Nodal signaling may
function to suppress elements of this cell fate in undifferenti-
ated in ES cells.Morework needs to be done to determine if this
derepression of trophectoderm genes is BMP-dependent.
Mouse ES cells do not readily contribute to the trophectoderm
lineages when introduced to a blastocyst; however, some differ-
entiation conditions have been described to allow such differ-
entiation in vitro (54, 55). Thus, furtherwork is needed to ascer-
tain whether autocrine Nodal signaling inhibits the propensity
of ES cells to differentiate to a trophectoderm pathway, and if
this function is achieved by attenuating BMP activity. Nodal
activity in ES cells is thus complex andmodulates both pluripo-
tency and prodifferentiation pathways.
Our data point to a role for Nodal signaling in attenuating,
but not abolishing, BMP signaling in undifferentiated ES cells.
Given that BMP signaling is essential for maintaining ES cells
under serum-free conditions, an important question remains as
to why ES cells utilize autocrine Nodal signaling to attenuate
BMP signaling. Both ES cells and the early epiblast are thought
to represent a “poised state,” in which a variety of prodifferen-
tiation pathways are present but inhibited by extrinsic signals
such as BMP and LIF to maintain ES cell identity and pluripo-
tency (6, 56). Although BMP signaling is essential for maintain-
ing ES cells in an undifferentiated state, numerous studies have
shown that under differentiating conditions BMP signaling also
strongly promotes differentiation of ES cells toward certain
mesodermal lineages (57), in many ways mimicking the devel-
opmental progression of mesoderm differentiation in the gas-
trulating embryo. Thus, attenuated BMP activity in undifferen-
tiated ES cellsmay be important to repress the differentiation of
ES cells to some mesodermal, and perhaps trophectodermal
pathways. In addition to functioning to modulate BMP signal-
ing, the active Nodal signaling pathway in ES cells may also
represent a poised signaling pathway, be invoked upon BMP
withdrawal, and be further enhanced during differentiation to
certain early developmental lineages. Multiple studies have
shown that Activin and Nodal signaling promote the differen-
tiation of definitive endoderm and mesoderm fate choices (58,
59). Thus, the activities of both the Nodal signaling and BMP
signaling aremultifaceted in ES cells, and appear to be essential
to both maintain ES cell homeostasis while also required for
certain differentiation pathways. Themultifaceted functions of
these pathways in both pluripotency and differentiation would
thus require a complexmeans to regulating the activity of these
pathways to control the ES cell phenotype.
Interactions between Nodal and BMP Signaling in Other
Experimental Systems—Our data point to a regulation of the
BMP pathway in ES cells via Nodal signaling through an intra-
cellular regulation of Smad7. Activin/Nodal signaling canmod-
ulate BMP signaling activity in a variety of systems, including
FIGURE 6. Model of Nodal-Smad2 signaling regulation of the BMP pluri-
potency pathway in mouse ES cells. Nodal-Smad2 signaling regulates a
significant number of genes in undifferentiated ES cells. Positively regulated
targets include genes characteristic of the mesendoderm developmental lin-
eage. Genes negatively regulated by Nodal signaling include some tropho-
blast markers; the mechanism of this regulation remains to be determined.
The regulation of Id gene expression by Nodal-Smad2 is indirect, via the BMP
signaling pathway. The transcriptional regulation of Smad7 by Nodal signal-
ing is the major contributor to the modulation of the BMP signaling pathway.
BMP pathway activation and Id gene expression are essential components to
maintain ES cell pluripotency.
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dorsal-ventral patterning of the mesoderm during gastrulation
(60) and induction of trophoblast differentiation from human
ES cells (61). In many contexts, Activin/Nodal signaling has a
negative effect on BMP signaling via regulation of secreted
BMP ligand antagonists such as noggin, follistatin, and chordin
(35). These extracellular antagonists permit localized activity of
both Activin/Nodal and BMP signaling in the prospective dor-
sal and ventral sides of the embryo, respectively. The connec-
tivity between theNodal-Smad2 pathwaywith the pro-pluripo-
tency program of BMP-Smad1/5 suggests that Nodal signaling
modulates the pluripotent state of ES cells. Pharmacological
inhibition of Smad2 signaling demonstrated that Smad2 signal-
ing is required for the efficient outgrowth of the inner cell mast
from blastocysts yet is not necessary for maintenance of Oct4
expression in mouse ES cells (62). Inhibition of Nodal-Smad2
signaling reduces proliferation of ES cells grown in media with
serum or knock-out serum replacement (16). We confirmed
that long term Nodal-Smad2 inhibition slows the proliferation
of ES cells in a definedmedia supplementedwith LIF andBMP4
and, of interest, the SB431542 treatment appears to reduce the
spontaneous differentiation on the edge of ES cell colonies
(data not shown). However, long term treatment of ES cells
with SB431542 in the absence of BMP supplement resulted in a
decline of the pluripotent marker Nanog expression by over
50% (supplemental Fig. 2B). Thus, although the cross-talk
between the Nodal and BMP pathways is long lasting, inhibi-
tion of Smad2 signaling alone is not sufficient to support ES cell
self-renewal.
The culture conditions required to induce and sustain the
pluripotent state of mouse and human ES cells greatly differ.
LIF maintains undifferentiated mouse ES cells (2, 3), whereas
human ES cells rely on Activin/Nodal signaling in combination
with fibroblast growth factors (63–65). Activated BMP signal-
ing stimulates differentiation in human ES cells (66) but main-
tains pluripotency in mouse ES cells (5). The disparities
between extrinsic pluripotent signals of the mouse and human
cells may in part arise from these cells representing slightly
different stages of embryonic development (67). In common
with our analyses, human ES cells induce Smad1 phosphoryla-
tion following inhibition of Smad2 signaling and reduce
pSmad1 levels after Activin stimulation (61, 62). Themolecular
mechanisms of Nodal and BMP interconnectivity, including
Smad7 modulation, may be shared in ES cells of different spe-
cies even though the functionalities of these pathways differ.
Functions of Nodal-related Signaling in iPSCs—Induced plu-
ripotent stem cells (iPSCs) were first generated through viral
transduction of specific transcription factors (Oct4, Sox2,
c-Myc, and Klf4) into somatic cells to reprogram them to the
embryonic state (68, 69). Current work is focusing on potential
small molecules to replace the oncogenic factors and increase
reprogramming efficiency (70). In combination with inhibition
of the MEK pathway, SB431542 increased efficiency of fully
reprogrammed human iPSCs from fibroblasts over 100-fold
(71). Chemical inhibition of Smad2 reduced spontaneous dif-
ferentiation and increased clonal expansion efficiency of iPSCs
(72). Further analysis revealed that inhibition of Smad2 signal-
ing replaces the need for transduction of Sox2 by inducing
expression of Nanog in iPSCs (73). The biochemical mecha-
nism for the enhanced reprogramming of somatic cells by
Smad2 inhibition is unknown. SB431542 treatment of mouse
ES cells grown in ES media increases the percentage of Nanog-
positive cells and expression of Oct4, Nanog, Stella, and Id
genes (data not shown). Thus, the linkage between Nodal-
Smad2 inhibition and BMP-Smad1/5 activation found in
mouse ES cells may also apply to iPSCs. Future work will be
needed to determine if the molecular mechanisms by which
inhibition of Nodal signaling enhances the pluripotency of ES
cells and iPSCs have a common molecular basis.
Acknowledgments—We gratefully acknowledge the technical exper-
tise of Lucy Liu. We thank the University of Kansas Medical Center-
Microarray Facility for generating array data sets and Aris Mousta-
kas for providing the CAGA12 plasmid.
REFERENCES
1. Evans, M. J., and Kaufman, M. H. (1981) Nature 292, 154–156
2. Smith, A.G., Heath, J. K., Donaldson, D.D.,Wong,G.G.,Moreau, J., Stahl,
M., and Rogers, D. (1988) Nature 336, 688–690
3. Williams, R. L., Hilton, D. J., Pease, S., Willson, T. A., Stewart, C. L., Gear-
ing, D. P., Wagner, E. F., Metcalf, D., Nicola, N. A., and Gough, N. M.
(1988) Nature 336, 684–687
4. Qi, X., Li, T. G., Hao, J., Hu, J., Wang, J., Simmons, H., Miura, S., Mishina,
Y., and Zhao, G. Q. (2004) Proc. Natl. Acad. Sci. U.S.A. 101, 6027–6032
5. Ying, Q. L., Nichols, J., Chambers, I., and Smith, A. (2003) Cell 115,
281–292
6. Ying, Q. L., Wray, J., Nichols, J., Batlle-Morera, L., Doble, B., Woodgett, J.,
Cohen, P., and Smith, A. (2008) Nature 453, 519–523
7. Lasorella, A., Uo, T., and Iavarone, A. (2001) Oncogene 20, 8326–8333
8. Sikder, H. A., Devlin, M. K., Dunlap, S., Ryu, B., and Alani, R. M. (2003)
Cancer Cell 3, 525–530
9. Hollnagel, A., Oehlmann, V., Heymer, J., Rüther, U., and Nordheim, A.
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